Iambic Therapeutics, Inc.

Iambic Therapeutics is a clinical-stage biotechnology company that utilizes an AI-enabled small-molecule discovery platform to develop drug candidates for oncology and other diseases. The company, founded in 2019 and based in San Diego, California, integrates proprietary, large-scale artificial intelligence with automated chemistry and biology experimentation. This approach, termed "molecular superintelligence," aims to streamline the entire drug discovery and development process, from hit identification to clinical developability. Iambic's platform incorporates technologies such as Enchant, a multimodal AI model for predicting preclinical and clinical properties, and NeuralPLexer, a generative AI for biomolecular structure prediction. The company's pipeline is primarily focused on oncology, with programs targeting HER2-driven cancers, cell-cycle dysregulation pathways, and other oncology targets. Iambic also has a neurological indication program in discovery. Its lead program, IAM1363, is an oral, highly selective, pan-mutant, brain-penetrant HER2 inhibitor currently in a Phase 1/1b basket study for HER2-altered solid tumors. Other preclinical candidates include IAM217, a brain-penetrant, allosteric KIF18A inhibitor, and IAM-C1, a selective dual CDK2/4 inhibitor, with planned IND submissions in Q4 2026. Iambic Therapeutics also engages in partnerships with pharmaceutical and technology companies to apply its platform to additional targets and indications. Sources: [1] https://www.thepharmaletter.com/ones-to-watch/iambic-therapeutics [2] https://stockanalysis.com/stocks/iam/company/ [3] https://tracxn.com/d/companies/iambic-therapeutics/__7mdxVh9vYPwq7ZQgVIyYlT_LO5RP9D1K79f4mg_vAK4 [4] https://www.tradingview.com/news/tradingview:aa5e5b9bf058a:0-iambic-therapeutics-ai-driven-drug-discovery-platform-files-for-nasdaq-global-select-market-ipo/ [5] https://www.iposcoop.com/ipo/iambic-therapeutics/ [6] https://mtec-sc.org/life-sciences/iambic-therapeutics-inc